Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type

Alzheimer Disease Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00041678
• Other study ID #: CN138-005
• Status: Completed
• Phase: Phase 3
• First received: July 12, 2002
• Last updated: November 7, 2013
• Start date: January 2000
• Est. completion date: March 2003

Study information

• Verified date: September 2007
• Source: Otsuka Pharmaceutical Development & Commercialization, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to learn if aripiprazole is safe and effective in the treatment of psychosis associated with dementia of the Alzheimer's type.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Est. completion date: March 2003
• Est. primary completion date: March 2003
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 55 Years to 95 Years

Eligibility

Inclusion Criteria:

• Institutionalized patients with Alzheimer's Disease

Study Design

Primary Purpose: Treatment

Related Conditions & MeSH terms

• Alzheimer Disease

Intervention

Drug:
• aripiprazole

Locations

Country	Name	City	State
United States	Local Institution	Bennington	Vermont
United States	Local Institution	Burlington	Vermont
United States	Local Institution	Miami	Florida
United States	Local Institution	Milwaukee	Wisconsin
United States	Local Institution	Nashville	Tennessee
United States	Local Institution	Rosemead	California

Sponsors (1)

Lead Sponsor	Collaborator
Otsuka Pharmaceutical Development & Commercialization, Inc.

Country where clinical trial is conducted

United States, 

External Links

•   BMS Clinical Trials Disclosure
•   For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm